BRIEF published on 09/03/2026 at 07:35, 6 days 1 hour ago Sensorion receives authorization to initiate a clinical trial in France Gene Therapy Clinical Trial France Hearing Sensory
BRIEF published on 09/03/2026 at 07:35, 6 days 1 hour ago Sensorion Receives Approval for SENS-601 Trial in France Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-601
PRESS RELEASE published on 09/03/2026 at 07:30, 6 days 1 hour ago Inside Information / Other news releases Sensorion receives approval from ANSM to start Phase I/II clinical trial of SENS-601, a gene therapy for GJB2-related hearing loss in France. Event hosted to discuss program details Gene Therapy Clinical Trial Sensorion SENS-601 GJB2-related Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 2 months 29 days ago Sensorion Advances SENS-601 for GJB2-Related Hearing Loss Clinical Trials Gene Therapy Sensorion SENS-601 GJB2 Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 2 months 29 days ago Sensorion Refocuses on SENS-601 for Gene Therapy Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
PRESS RELEASE published on 06/10/2026 at 07:30, 2 months 29 days ago Inside Information / Other news releases Sensorion achieves key regulatory milestones for SENS-601 addressing GJB2-related hearing loss and discontinues SENS-501. Fast Track procedure granted by ANSM in France. Clinical trials planned in Canada and U.S. IND submission targeted by 2026 Clinical Trials Gene Therapy Sensorion Regulatory Milestones GJB2-related Hearing Loss
BRIEF published on 05/18/2026 at 07:35, 3 months 22 days ago Sensorion Appoints Fred Chereau as CEO Biotechnology CEO Appointment Gene Therapy Sensorion Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 3 months 22 days ago Fred Chereau appointed Managing Director of Sensorion Gene Therapy General Management Hearing Loss Sensory Fred Chereau
PRESS RELEASE published on 05/18/2026 at 07:30, 3 months 22 days ago Inside Information / Other news releases Sensorion appoints Fred Chereau as Chief Executive Officer, bringing extensive leadership experience in gene therapy and rare diseases. Amit Munshi continues as Chairman of the Board Gene Therapy Chief Executive Officer Rare Diseases Sensorion Fred Chereau
BRIEF published on 05/13/2026 at 07:35, 3 months 27 days ago Results of the Sensorion General Meeting Biotechnology General Assembly Resolutions Adopted Hearing Loss Sensory
Published on 09/09/2026 at 00:35, 8 hours 15 minutes ago Troubadour Resources Announces Non-Brokered Unit Private Placement and Convertible Debenture Financing
Published on 09/09/2026 at 00:25, 8 hours 25 minutes ago Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
Published on 09/08/2026 at 23:35, 9 hours 15 minutes ago The Western Investment Company of Canada Limited Announces Intention to Commence Normal Course Issuer Bid
Published on 09/08/2026 at 22:30, 10 hours 20 minutes ago Grid Metals Announces Positive Mineralogical Results at Falcon West, Engages SGS Canada for Ore Sorting Test Work, and Announces Investor Relations Agreements
Published on 09/08/2026 at 22:15, 10 hours 35 minutes ago GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Published on 09/09/2026 at 08:30, 20 minutes ago M1 Kliniken AG publishes Half-Year Report 2026: Beauty EBIT up 23.8% to EUR 18.6 million
Published on 09/09/2026 at 08:30, 20 minutes ago Predictiv AI Qualifies Across All Three Bands of Government of Canada Artificial Intelligence Source List
Published on 09/09/2026 at 07:30, 1 hour 20 minutes ago Gimv Anchor invests in Batenburg Techniek, a leading Dutch provider of industrial electrification and automation solutions
Published on 09/08/2026 at 11:00, 21 hours 50 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 09/08/2026 at 10:21, 22 hours 29 minutes ago Disclosure of Share Capital and Voting Rights as of August 31, 2026
Published on 09/07/2026 at 19:00, 1 day 13 hours ago Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 1 day 14 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
